EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Remdesivir in COVID‐19: A Focus on Pediatric Cardiac Patients

Dima Bsat iD, Dalia Safi iD, Mariam Arabi iD

Canadian Journal of Infectious Diseases and Medical Microbiology · 2026-01 · 2026 (1)

DOI: 10.1155/cjid/4700812 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Canadian Journal of Infectious Diseases and Medical Microbiology, online erschienen am 24.02.2026. Verfasst von Dima Bsat und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon, aubmc.org.lb. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The coronavirus disease 2019 (COVID‐19) pandemic has presented a significant global health challenge that necessitated the immediate search for various therapeutic modalities. Remdesivir, an antiviral drug inhibiting RNA‐dependent RNA polymerase (RdRp), was among the most heavily used drugs against COVID‐19. Of the several randomized controlled trials studying the efficacy of remdesivir, the vast majority were studied on the adult population. Results remain contradictory, with some studies supporting the high efficacy of remdesivir while others highlighting the lack of significance of its antiviral effects. Given the lack of focus on the pediatric population, the antiviral effects of remdesivir in cardiac pediatric patients, who are particularly vulnerable, remain especially under‐investigated. This literature review explores current literature on remdesivir’s mechanism of action and efficacy against COVID‐19, especially in the pediatric cardiac population. Therefore, by combining results of studies from randomized controlled trials and retrospective studies in the adult and pediatric populations, this literature review underlines current knowledge gaps and highlights the need for studies targeting specific ages and comorbidities to effectively treat patients at higher risk of adverse events.

Schlagwörter

Stichwörter der Autor:innen

COVID-19SARS-CoV-2coronavirusremdesivir

Autor:innen und Institutionen

  • Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon, aubmc.org.lb.
  • Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, American University of Beirut Medical Center, Beirut, Lebanon, aubmc.org.lb.

ORCID-Profile: Dima Bsat, Dalia Safi, Mariam Arabi

Zitieren

APA

Bsat, D., Safi, D., & Arabi, M. (2026). Remdesivir in COVID‐19: A Focus on Pediatric Cardiac Patients. Canadian Journal of Infectious Diseases and Medical Microbiology, 2026(1). https://doi.org/10.1155/cjid/4700812

Vancouver

Bsat D, Safi D, Arabi M. Remdesivir in COVID‐19: A Focus on Pediatric Cardiac Patients. Canadian Journal of Infectious Diseases and Medical Microbiology. 2026;2026(1). doi:10.1155/cjid/4700812

BibTeX
@article{Bsat2026,
  author = {Bsat, Dima and Safi, Dalia and Arabi, Mariam},
  title = {Remdesivir in COVID‐19: A Focus on Pediatric Cardiac Patients},
  journal = {Canadian Journal of Infectious Diseases and Medical Microbiology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/cjid/4700812}
}
Kostenlos starten →